What’s next after Ozempic and Wegovy and the like? How about a drug in development which releases all the relevant hormones, and not just GLP-1. And doesn’t require injecting. Dr. Steffen-Sebastian Bolz from Aphaia (ah-phi-ah) Pharma explains their approach, currently in Phase 2.

eFFECTOR Therapeutics has responded with Selective Translation Regulator Inhibitors (STRIs). These STRIs are precision instruments dismantling the foundations of tumour growth, immune evasion, and resistance to treatment.

Elicio Therapeutics, outlined the SITC presentation on ELI-002 and plans for future cancer vaccine development.

The reason that I joined Elicio was in part because my father had KRAS-mutated colorectal cancer.

Capricor Therapeutics, for instance, is developing cell and exosome-based technologies to treat or prevent a broad range of diseases.

Recce Pharmaceuticals is at the forefront of developing a new class of synthetic anti-infectives with a unique mechanism of action.

In this episode of Breakthrough Economy, MindMed CEO Robert Barrow chats with Host Jen Rogers about how his company, which was the first psychedelic pharmaceutical company to go public, is working to unlock the full therapeutic potential of psychedelics and other novel therapeutic targets.

Cynthia Pussinen knew she wanted to work in STEM fields by the time she was a teenager, she received a full scholarship to study nuclear engineering but after two years changed to chemistry for her major.